

Luiz Gonzaga Coelho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6569096/publications.pdf>

Version: 2024-02-01

39
papers

2,142
citations

394421

19
h-index

302126

39
g-index

41
all docs

41
docs citations

41
times ranked

2658
citing authors

#	ARTICLE	IF	CITATIONS
1	Kyoto global consensus report on <i>Helicobacter pylori</i> gastritis. <i>Gut</i> , 2015, 64, 1353-1367.	12.1	1,256
2	World Gastroenterology Organisation Global Guideline. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 383-388.	2.2	97
3	Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. <i>Gut</i> , 2016, 65, 721-725.	12.1	72
4	New once-daily, highly effective rescue triple therapy after multiple <i>Helicobacter pylori</i> treatment failures: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 783-787.	3.7	55
5	Review: Epidemiology of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2020, 25, e12734.	3.5	52
6	IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 97-121.	0.8	47
7	Botulinum A Toxin Injected into the Gastric Wall for the Treatment of Class III Obesity: A Pilot Study. <i>Obesity Surgery</i> , 2006, 16, 335-343.	2.1	43
8	Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. <i>Life Sciences</i> , 2009, 84, 641-649.	4.3	43
9	Effectiveness of Unsedated Transnasal Endoscopy With White-light, Flexible Spectral Imaging Color Enhancement, and Lugol Staining for Esophageal Cancer Screening in High-risk Patients. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 314-321.	2.2	36
10	Failure of <i>Helicobacter pylori</i> Treatment After Regimes Containing Clarithromycin: New Practical Therapeutic Options. <i>Helicobacter</i> , 2008, 13, 572-576.	3.5	34
11	Brazilian Green Propolis on <i>Helicobacter pylori</i> Infection. A Pilot Clinical Study. <i>Helicobacter</i> , 2007, 12, 572-574.	3.5	33
12	World Gastroenterology Organisation Global Guideline: <i>Helicobacter pylori</i> in Developing Countries. <i>Journal of Digestive Diseases</i> , 2011, 12, 319-326.	1.5	32
13	The presence of <i>Helicobacter Pylori</i> in postmenopausal women is not a factor to the decrease of bone mineral density. <i>Arquivos De Gastroenterologia</i> , 2007, 44, 266-270.	0.8	31
14	Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity. <i>International Journal of Nanomedicine</i> , 2012, 7, 5259.	6.7	30
15	Detection of <i>Helicobacter pylori</i> resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. <i>World Journal of Gastroenterology</i> , 2016, 22, 7587.	3.3	30
16	3rd BRAZILIAN CONSENSUS ON <i>Helicobacter pylori</i> . <i>Arquivos De Gastroenterologia</i> , 2013, 50, 81-96.	0.8	27
17	Acute Toxicity Study of Cisplatin Loaded Long-Circulating and pH-Sensitive Liposomes Administered in Mice. <i>Journal of Biomedical Nanotechnology</i> , 2012, 8, 229-239.	1.1	26
18	<i>Campylobacter pylori</i> in esophagus, antrum, and duodenum. <i>Digestive Diseases and Sciences</i> , 1989, 34, 445-448.	2.3	22

#	ARTICLE	IF	CITATIONS
19	A Rapid HPLC-ESI-MS/MS Method for Determination of Dihydrouracil/Uracil Ratio in Plasma: Evaluation of Toxicity to 5-Fluorouracil in Patients With Gastrointestinal Cancer. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 59-66.	2.0	19
20	Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice. <i>Experimental Biology and Medicine</i> , 2011, 236, 808-815.	2.4	15
21	Diagnosis of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2017, 22, e12404.	3.5	14
22	Assessment of effectiveness of different dosage regimens of pantoprazole in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis. <i>Arquivos De Gastroenterologia</i> , 2002, 39, 123-125.	0.8	11
23	Cystic fibrosis, gastroduodenal inflammation, duodenal ulcer, and <i>H. pylori</i> infection: The "cystic fibrosis paradox" revisited. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 377-383.	0.7	11
24	Clinical Management of <i>Helicobacter pylori</i> : The Latin American Perspective. <i>Digestive Diseases</i> , 2014, 32, 302-309.	1.9	11
25	MOLECULAR DETECTION OF CLARITHROMYCIN AND FLUOROQUINOLONES RESISTANCE IN <i>HELICOBACTER PYLORI</i> INFECTION, DIRECTLY APPLIED TO GASTRIC BIOPSIES, IN AN URBAN BRAZILIAN POPULATION. <i>Arquivos De Gastroenterologia</i> , 2016, 53, 113-117.	0.8	9
26	Fat Malabsorption Assessed by ¹⁴ C-triolein Breath Test in HIV-positive Patients in Different Stages of Infection. <i>Journal of Clinical Gastroenterology</i> , 2000, 30, 403-408.	2.2	8
27	Does low dose ¹³ C-urea breath test maintain a satisfactory accuracy in diagnosing <i>Helicobacter pylori</i> infection?. <i>Arquivos De Gastroenterologia</i> , 2011, 48, 104-108.	0.8	7
28	<i>Campylobacter pyloridis</i> in the upper gastrointestinal tract: a Brazilian study. <i>Arquivos De Gastroenterologia</i> , 1987, 24, 5-9.	0.8	7
29	Leukocyte-technetium-99m uptake in Crohn's disease: Does it show subclinical disease?. <i>World Journal of Gastroenterology</i> , 2010, 16, 365.	3.3	6
30	Performance of the ¹³ C-urea breath test for the diagnosis of <i>H. pylori</i> infection using a substrate synthesized in Brazil: A preliminary study. <i>Clinics</i> , 2018, 73, e16-553.	1.5	5
31	<i>HELICOBACTER PYLORI</i> CHRONIC GASTRITIS ON PATIENTS WITH PREMALIGNANT CONDITIONS: OLGA AND OLGIM EVALUATION AND SERUM BIOMARKERS PERFORMANCE. <i>Arquivos De Gastroenterologia</i> , 2021, 58, 39-47.	0.8	4
32	<i>Helicobacter pylori</i> and colorectal neoplasms: a concise review. <i>Arquivos De Gastroenterologia</i> , 2021, 58, 114-119.	0.8	4
33	PROSPECTIVE STUDY FOR VALIDATION OF A SINGLE PROTOCOL FOR THE ¹³ C-UREA BREATH TEST USING TWO DIFFERENT DEVICES IN THE DIAGNOSIS OF <i>H. PYLORI</i> INFECTION. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 197-201.	0.8	4
34	Once-daily <i>Helicobacter pylori</i> treatment to family members of gastric cancer patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 832-833.	0.4	3
35	Rescue therapy with levofloxacin after multiple <i>H. pylori</i> treatment failures: Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 654-655.	3.7	3
36	STRUCTURING A FECAL MICROBIOTA TRANSPLANTATION CENTER IN A UNIVERSITY HOSPITAL IN BRAZIL. <i>Arquivos De Gastroenterologia</i> , 2020, 57, 434-458.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Increased parietal cell density in patients with perforated duodenal ulcer: Comparison with non-complicated duodenal ulcer patients. <i>Gastroenterology</i> , 2001, 120, A250.	1.3	2
38	Mucosa-Associated Lymphoid Tissue Gastric Lymphoma Regression in a Renal Transplant Patient After Conversion of the Immunosuppression to Sirolimus: A Case Report. <i>Transplantation Proceedings</i> , 2009, 41, 959-961.	0.6	2
39	Gastric mucosa histopathology, <i>Helicobacter pylori</i> infection, and bone mineral density in postmenopausal women. <i>Gastroenterology</i> , 2003, 124, A545.	1.3	0